Novo Nordisk Aktie
42,10
EUR
+0,35
EUR
+0,83
%
42,20
EUR
+0,38
EUR
+0,90
%
Novo Nordisk jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Werbung
Novo Nordisk Aktie Analyse
| 03.10.22 | Novo Nordisk Overweight | Barclays Capital | |
| 21.09.22 | Novo Nordisk Buy | Deutsche Bank AG | |
| 22.08.22 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 15.08.22 | Novo Nordisk Overweight | Barclays Capital | |
| 05.08.22 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 05.08.22 | Novo Nordisk Buy | Deutsche Bank AG | |
| 04.08.22 | Novo Nordisk Overweight | Barclays Capital | |
| 03.08.22 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
|
Werbung
|
|||
| 03.08.22 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 18.07.22 | Novo Nordisk Overweight | Barclays Capital | |
| 14.07.22 | Novo Nordisk Outperform | Bernstein Research | |
| 13.07.22 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 24.06.22 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 21.06.22 | Novo Nordisk Buy | Deutsche Bank AG | |
| 16.06.22 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 13.06.22 | Novo Nordisk Overweight | Barclays Capital | |
| 08.06.22 | Novo Nordisk Buy | Deutsche Bank AG | |
| 07.06.22 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 03.06.22 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 24.05.22 | Novo Nordisk Buy | Deutsche Bank AG | |
| 12.05.22 | Novo Nordisk Overweight | Barclays Capital | |
| 11.05.22 | Novo Nordisk Buy | Deutsche Bank AG | |
| 05.05.22 | Novo Nordisk Outperform | Bernstein Research | |
| 05.05.22 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 04.05.22 | Novo Nordisk Buy | Deutsche Bank AG | |
| 03.05.22 | Novo Nordisk Buy | Deutsche Bank AG | |
| 29.04.22 | Novo Nordisk Outperform | Bernstein Research | |
| 29.04.22 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 21.04.22 | Novo Nordisk Outperform | Bernstein Research | |
| 12.04.22 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 01.04.22 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 16.03.22 | Novo Nordisk Buy | Deutsche Bank AG | |
| 04.03.22 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 15.02.22 | Novo Nordisk Overweight | Barclays Capital | |
| 03.02.22 | Novo Nordisk Outperform | Bernstein Research | |
| 02.02.22 | Novo Nordisk Outperform | Bernstein Research | |
| 02.02.22 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 31.01.22 | Novo Nordisk Overweight | Barclays Capital | |
| 26.01.22 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 24.01.22 | Novo Nordisk Outperform | Bernstein Research | |
| 04.01.22 | Novo Nordisk Outperform | Bernstein Research | |
| 21.12.21 | Novo Nordisk Overweight | Barclays Capital | |
| 07.12.21 | Novo Nordisk Buy | Deutsche Bank AG | |
| 29.11.21 | Novo Nordisk Buy | Deutsche Bank AG | |
| 26.11.21 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 26.11.21 | Novo Nordisk Outperform | Bernstein Research | |
| 22.11.21 | Novo Nordisk Overweight | Barclays Capital | |
| 18.11.21 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 11.11.21 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 04.11.21 | Novo Nordisk Overweight | Barclays Capital | |
Werbung
Werbung